Komori
Semi-Annual Report4563AnGes,Inc.Pharmaceuticals

Semi-Annual Report — FY2026 H1

What AnGes,Inc. reported for the period from 2026-01-01 to 2026-12-31.

How much it says
57Typical
What moved here
17named for the first time
Its own wording
46terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

In connection with its liquidity and going-concern considerations, the company acquired and cancelled the 46th series of stock acquisition rights, terminated the unsecured privately placed bond facility agreement and then redeemed the second unsecured bond. It subsequently issued the 47th and 48th series of stock acquisition rights and the second unsecured convertible bond with stock acquisition rights through a third-party allotment to the GP Fund (Growth Partners) and also entered into a business alliance agreement.

Komori's summary of this document, not the document's own words.
57Typical
How much this filing saysA weighted roll-up of 9 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 34 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
96
Very detailed
Magnitude of change
45
Typical
Strategic shift
49
Typical
Capital movements
50
Typical
Disclosure Gaps
68
Detailed
Change in Risk
55
Typical
Financial and Capital Policy
7
Almost nothing
Product portfolio
79
Very detailed
Technology Position
50
Typical
Confidence in Strategic Bets
R&D spend27億円Money spent making new things.
Cash left over-28億円Cash from the business, less what went into equipment.
Spent on equipment13百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
AnGes,Inc. — FY2026 H1 | Komori